Peficitinib

Peficitinib (brand name Smyraf) is a pharmaceutical drug used for the treatment of rheumatoid arthritis. It belongs to the class of drugs known as Janus kinase inhibitors (JAK inhibitors).^[1][2]

Peficitinib

Clinical data
Trade names	Smyraf
Other names	ASP015K; JNJ-54781532
ATC code	L04AF06 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
CAS Number	944118-01-8
PubChem CID	57928403
UNII	HPH1166CKX
KEGG	D10721
Chemical and physical data
Formula	C18H22N4O2
Molar mass	326.400 g·mol−1
3D model (JSmol)	Interactive image
SMILES NC(=O)c1cnc2[nH]ccc2c1NC1[C@H]2CC3C[C@@H]1CC(O)(C3)C2
InChI InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9?,10-,11+,1 Y Key:DREIJXJRTLTGJC-JQCLMNFQSA-N Y

Peficitinib was approved for use in Japan in 2019.^[3]